OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PKP55

Peak Processing Ltd

PharmaceuticalsVerified

Peak Processing Ltd operates with a negative equity position of -AUD 574,000 and a debt-to-equity ratio of -10.65, indicating a highly leveraged capital structure with liabilities exceeding assets. The company’s liquidity is constrained, as reflected in a current ratio of 0.66, suggesting limited ability to meet short-term obligations. Free cash flow is negative at -AUD 4,069,000, and operating cash flow is -AUD 8,407,000, signaling cash burn and operational inefficiency. Profitability metrics are mixed. The company reports a return on equity of 14.54%, which is unusually high given the negative equity, and a return on assets of -0.41%, indicating poor asset utilization. Operating income is -AUD 3,983,000, and net income is -AUD 8,347,000, reflecting a significant loss position. These results fall below the typical performance of the Pharmaceuticals industry, which prioritizes R&D efficiency and margin expansion as key metrics. The company’s revenue is not segmented by product or geography in the latest financials, but its total revenue of AUD 15,562,000 suggests a concentration in a limited number of markets or therapeutic areas. Without disclosed geographic breakdowns, it is unclear whether the company is exposed to high-risk or high-growth regions. Growth trajectory is negative, with no disclosed revenue growth rates or forward-looking guidance. The company’s operating income and net income are declining, and capital expenditures of -AUD 941,000 suggest reduced investment in long-term capabilities. Risk factors include liquidity constraints, with total liabilities exceeding total assets by AUD 574,000, and a negative net cash position after subtracting total debt. Dilution risk is currently low, as shares outstanding remain unchanged between basic and diluted measures. However, the company’s negative equity and cash flow position may necessitate future capital raises, which could dilute existing shareholders. Recent filings and transcripts do not disclose material events or strategic shifts, but the company’s financial position suggests operational challenges that may require restructuring or external financing.

30-day price · PKP+0.00 (+0.0%)
Low$0.01High$0.02Close$0.02As of17 May, 00:00 UTC
Profile
CompanyPeak Processing Ltd
TickerPKP.AX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Peak Processing Ltd develops and commercializes pharmaceutical products, generating revenue primarily through sales of its drug formulations and research partnerships.

Classification. Peak Processing Ltd is classified in the Pharmaceuticals industry under the Healthcare economic sector, with a confidence level of 0.92 based on verified market data.

Peak Processing Ltd operates with a negative equity position of -AUD 574,000 and a debt-to-equity ratio of -10.65, indicating a highly leveraged capital structure with liabilities exceeding assets. The company’s liquidity is constrained, as reflected in a current ratio of 0.66, suggesting limited ability to meet short-term obligations. Free cash flow is negative at -AUD 4,069,000, and operating cash flow is -AUD 8,407,000, signaling cash burn and operational inefficiency. Profitability metrics are mixed. The company reports a return on equity of 14.54%, which is unusually high given the negative equity, and a return on assets of -0.41%, indicating poor asset utilization. Operating income is -AUD 3,983,000, and net income is -AUD 8,347,000, reflecting a significant loss position. These results fall below the typical performance of the Pharmaceuticals industry, which prioritizes R&D efficiency and margin expansion as key metrics. The company’s revenue is not segmented by product or geography in the latest financials, but its total revenue of AUD 15,562,000 suggests a concentration in a limited number of markets or therapeutic areas. Without disclosed geographic breakdowns, it is unclear whether the company is exposed to high-risk or high-growth regions. Growth trajectory is negative, with no disclosed revenue growth rates or forward-looking guidance. The company’s operating income and net income are declining, and capital expenditures of -AUD 941,000 suggest reduced investment in long-term capabilities. Risk factors include liquidity constraints, with total liabilities exceeding total assets by AUD 574,000, and a negative net cash position after subtracting total debt. Dilution risk is currently low, as shares outstanding remain unchanged between basic and diluted measures. However, the company’s negative equity and cash flow position may necessitate future capital raises, which could dilute existing shareholders. Recent filings and transcripts do not disclose material events or strategic shifts, but the company’s financial position suggests operational challenges that may require restructuring or external financing.
Key takeaways
  • Peak Processing Ltd is operating at a loss with negative equity and liquidity constraints.
  • The company’s return on equity is mathematically high due to negative equity, but its return on assets is negative, indicating poor asset performance.
  • Revenue concentration and geographic exposure are not disclosed, limiting visibility into diversification risks.
  • Capital expenditures are declining, and the company is burning cash, suggesting a lack of growth investment.
  • Liquidity risk is elevated, and the company may require external financing to sustain operations.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue$15.6M
Gross profit$7.5M
Operating income-$4.0M
Net income-$8.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$8.4M
CapEx-$941.0k
Free cash flow-$4.1M
Total assets$20.5M
Total liabilities$21.1M
Total equity-$574.0k
Cash & equivalents
Long-term debt$6.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$574.0k
Net cash-$6.1M
Current ratio0.7
Debt/Equity-10.7
ROA-40.7%
ROE14.5%
Cash conversion1.0%
CapEx/Revenue-6.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
MetricPKPActivity
Op margin-25.6%-2.9% medp25 -218.9% · p75 9.6%below median
Net margin-53.6%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin48.4%47.8% medp25 27.6% · p75 68.9%above median
CapEx / revenue-6.0%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity-1065.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 21:03 UTC#681c9fc3
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 21:05 UTCJob: 60192e5c